Complement factor 5 in asthma

Marsha Wills-Karp, Jörg Köhl, Christopher L. Karp

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The worldwide prevalence and severity of allergic asthma have increased dramatically in recent decades. Therapeutic advances have unfortunately not kept pace, and asthma morbidity and mortality continue to rise. The cardinal features of allergic asthma include airway hyperresponsiveness (AHR) to a variety of specific and nonspecific stimuli, excessive airway mucus production, pulmonary eosinophilia, and elevated concentrations of serum immunoglobulin E (IgE). Although asthma is multifactorial in origin, it is generally accepted that it arises as a result of inappropriate immunological responses to common environmental antigens in genetically susceptible individuals (1). Specifically, a multitude of evidence suggests that CD4 T cells producing Th2 cytokines (IL-4, IL-5, IL-13) play a pivotal role in disease pathogenesis. Although extensive research is ongoing into the processes underlying the development of deleterious immune responses to the ubiquitous, otherwise harmless, antigens that drive the expression of allergic asthma, these mechanisms remain a mystery.

Original languageEnglish (US)
Title of host publicationTherapeutic Targets in Airway Inflammation
PublisherCRC Press
Pages699-714
Number of pages16
ISBN (Electronic)9780203911471
ISBN (Print)9780824709563
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Complement C5
Asthma
Pulmonary Eosinophilia
Antigens
Interleukin-13
Interleukin-5
Mucus
Interleukin-4
Immunoglobulin E
Cytokines
Morbidity
T-Lymphocytes
Mortality
Serum
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wills-Karp, M., Köhl, J., & Karp, C. L. (2003). Complement factor 5 in asthma. In Therapeutic Targets in Airway Inflammation (pp. 699-714). CRC Press.

Complement factor 5 in asthma. / Wills-Karp, Marsha; Köhl, Jörg; Karp, Christopher L.

Therapeutic Targets in Airway Inflammation. CRC Press, 2003. p. 699-714.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wills-Karp, M, Köhl, J & Karp, CL 2003, Complement factor 5 in asthma. in Therapeutic Targets in Airway Inflammation. CRC Press, pp. 699-714.
Wills-Karp M, Köhl J, Karp CL. Complement factor 5 in asthma. In Therapeutic Targets in Airway Inflammation. CRC Press. 2003. p. 699-714
Wills-Karp, Marsha ; Köhl, Jörg ; Karp, Christopher L. / Complement factor 5 in asthma. Therapeutic Targets in Airway Inflammation. CRC Press, 2003. pp. 699-714
@inbook{7abc5359645b4abe8150b054cb672b39,
title = "Complement factor 5 in asthma",
abstract = "The worldwide prevalence and severity of allergic asthma have increased dramatically in recent decades. Therapeutic advances have unfortunately not kept pace, and asthma morbidity and mortality continue to rise. The cardinal features of allergic asthma include airway hyperresponsiveness (AHR) to a variety of specific and nonspecific stimuli, excessive airway mucus production, pulmonary eosinophilia, and elevated concentrations of serum immunoglobulin E (IgE). Although asthma is multifactorial in origin, it is generally accepted that it arises as a result of inappropriate immunological responses to common environmental antigens in genetically susceptible individuals (1). Specifically, a multitude of evidence suggests that CD4 T cells producing Th2 cytokines (IL-4, IL-5, IL-13) play a pivotal role in disease pathogenesis. Although extensive research is ongoing into the processes underlying the development of deleterious immune responses to the ubiquitous, otherwise harmless, antigens that drive the expression of allergic asthma, these mechanisms remain a mystery.",
author = "Marsha Wills-Karp and J{\"o}rg K{\"o}hl and Karp, {Christopher L.}",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824709563",
pages = "699--714",
booktitle = "Therapeutic Targets in Airway Inflammation",
publisher = "CRC Press",
address = "United States",

}

TY - CHAP

T1 - Complement factor 5 in asthma

AU - Wills-Karp, Marsha

AU - Köhl, Jörg

AU - Karp, Christopher L.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The worldwide prevalence and severity of allergic asthma have increased dramatically in recent decades. Therapeutic advances have unfortunately not kept pace, and asthma morbidity and mortality continue to rise. The cardinal features of allergic asthma include airway hyperresponsiveness (AHR) to a variety of specific and nonspecific stimuli, excessive airway mucus production, pulmonary eosinophilia, and elevated concentrations of serum immunoglobulin E (IgE). Although asthma is multifactorial in origin, it is generally accepted that it arises as a result of inappropriate immunological responses to common environmental antigens in genetically susceptible individuals (1). Specifically, a multitude of evidence suggests that CD4 T cells producing Th2 cytokines (IL-4, IL-5, IL-13) play a pivotal role in disease pathogenesis. Although extensive research is ongoing into the processes underlying the development of deleterious immune responses to the ubiquitous, otherwise harmless, antigens that drive the expression of allergic asthma, these mechanisms remain a mystery.

AB - The worldwide prevalence and severity of allergic asthma have increased dramatically in recent decades. Therapeutic advances have unfortunately not kept pace, and asthma morbidity and mortality continue to rise. The cardinal features of allergic asthma include airway hyperresponsiveness (AHR) to a variety of specific and nonspecific stimuli, excessive airway mucus production, pulmonary eosinophilia, and elevated concentrations of serum immunoglobulin E (IgE). Although asthma is multifactorial in origin, it is generally accepted that it arises as a result of inappropriate immunological responses to common environmental antigens in genetically susceptible individuals (1). Specifically, a multitude of evidence suggests that CD4 T cells producing Th2 cytokines (IL-4, IL-5, IL-13) play a pivotal role in disease pathogenesis. Although extensive research is ongoing into the processes underlying the development of deleterious immune responses to the ubiquitous, otherwise harmless, antigens that drive the expression of allergic asthma, these mechanisms remain a mystery.

UR - http://www.scopus.com/inward/record.url?scp=85056969371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056969371&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056969371

SN - 9780824709563

SP - 699

EP - 714

BT - Therapeutic Targets in Airway Inflammation

PB - CRC Press

ER -